Top

Published in:

Open Access 01-04-2020 | Insulins | Review

Post-Transplantation Diabetes Mellitus

Authors: Syed Haris Ahmed, Kathryn Biddle, Titus Augustine, Shazli Azmi

Published in: Diabetes Therapy | Issue 4/2020

Abstract

Solid organ transplantation (SOT) is an established therapeutic option for chronic disease resulting from end-stage organ dysfunction. Long-term use of immunosuppression is associated with post-transplantation diabetes mellitus (PTDM), placing patients at increased risk of infections, cardiovascular disease and mortality. The incidence rates for PTDM have varied from 10 to 40% between different studies. Diagnostic criteria have evolved over the years, as a greater understating of PTDM has been reached. There are differences in pathophysiology and clinical course of type 2 diabetes and PTDM. Hence, managing this condition can be a challenge for a diabetes physician, as there are several factors to consider when tailoring therapy for post-transplant patients to achieve better glycaemic as well as long-term transplant outcomes. This article is a detailed review of PTDM, examining the pathogenesis, diagnostic criteria and management in light of the current evidence. The therapeutic options are discussed in the context of their safety and potential drug-drug interactions with immunosuppressive agents.

Black CK, Termanini KM, Aguirre O, Hawksworth JS, Sosin M. Solid organ transplantation in the 21(st) century. Ann Transl Med. 2018;6(20):409.PubMedPubMedCentral

Valderhaug TG, Hjelmesaeth J, Jenssen T, Roislien J, Leivestad T, Hartmann A. Early posttransplantation hyperglycemia in kidney transplant recipients is associated with overall long-term graft losses. Transplantation. 2012;94(7):714–20.PubMed

Matas AJ, Gillingham KJ, Humar A, Ibrahim HN, Payne WD, Gruessner RWG, et al. Posttransplant diabetes mellitus and acute rejection: impact on kidney transplant outcome. Transplantation. 2008;85(3):338–43.PubMed

Pietrzak-Nowacka M, Safranow K, Dziewanowski K, Debska-Slizien A, Glyda M, Golembiewska E, et al. Impact of posttransplant diabetes mellitus on graft function in autosomal dominant polycystic kidney disease patients after kidney transplantation. Ann Acad Med Stetin. 2008;54(1):41–8.PubMed

Siraj ES, Abacan C, Chinnappa P, Wojtowicz J, Braun W. Risk factors and outcomes associated with posttransplant diabetes mellitus in kidney transplant recipients. Transplant Proc. 2010;42(5):1685–9.PubMed

Sharif A, Hecking M, de Vries APJ, Porrini E, Hornum M, Rasoul-Rockenschaub S, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Vol. 14, American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. United States; 2014. pp. 1992–2000.

Davidson J, Wilkinson A, Dantal J, Dotta F, Haller H, Hernandez D, et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation. 2003;75(10 Suppl):SS3–24.

Wilkinson A, Davidson J, Dotta F, Home PD, Keown P, Kiberd B, et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant. 2005;19(3):291–8.PubMed

Association AD. Diagnosis and classification of diabetes mellitus. Diabetes Care [Internet]. 2011;34 Suppl 1(Suppl 1):S62–9. https://www.ncbi.nlm.nih.gov/pubmed/21193628.

10.

Valderhaug TG, Jenssen T, Hartmann A, Midtvedt K, Holdaas H, Reisaeter AV, et al. Fasting plasma glucose and glycosylated hemoglobin in the screening for diabetes mellitus after renal transplantation. Transplantation. 2009;88(3):429–34.PubMed

11.

Sharif A, Moore RH, Baboolal K. The use of oral glucose tolerance tests to risk stratify for new-onset diabetes after transplantation: an underdiagnosed phenomenon. Transplantation. 2006;82(12):1667–72.PubMed

12.

Hecking M, Kainz A, Werzowa J, Haidinger M, Doller D, Tura A, et al. Glucose metabolism after renal transplantation. Diabetes Care. 2013;36(9):2763–71.PubMedPubMedCentral

13.

Hecking M, Werzowa J, Haidinger M, Horl WH, Pascual J, Budde K, et al. Novel views on new-onset diabetes after transplantation: development, prevention and treatment. Nephrol Dial Transplant. 2013;28(3):550–66.PubMedPubMedCentral

14.

Caillard S, Eprinchard L, Perrin P, Braun L, Heibel F, Moreau F, et al. Incidence and risk factors of glucose metabolism disorders in kidney transplant recipients: role of systematic screening by oral glucose tolerance test. Transplantation. 2011;91(7):757–64.PubMed

15.

Valderhaug TG, Hjelmesaeth J, Hartmann A, Roislien J, Bergrem HA, Leivestad T, et al. The association of early post-transplant glucose levels with long-term mortality. Diabetologia. 2011;54(6):1341–9.PubMedPubMedCentral

16.

Jenssen T, Hartmann A. Post-transplant diabetes mellitus in patients with solid organ transplants. Nat Rev Endocrinol. 2019;15(3):172–88.PubMed

17.

Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant. 2007;7(6):1506–14.PubMed

18.

Woodward RS, Schnitzler MA, Baty J, Lowell JA, Lopez-Rocafort L, Haider S, et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant. 2003;3(5):590–8.

19.

Jenssen T, Hartmann A. Emerging treatments for post-transplantation diabetes mellitus. Nat Rev Nephrol. 2015;11(8):465–77.PubMed

20.

Cho MS, Choi H-I, Kim I-O, Jung S-H, Yun T-J, Lee J-W, et al. The clinical course and outcomes of post-transplantation diabetes mellitus after heart transplantation. J Korean Med Sci. 2012;27(12):1460–7.PubMedPubMedCentral

21.

Kim HJ, Jung S-H, Kim J-J, Yun T-J, Kim JB, Choo SJ, et al. New-onset diabetes mellitus after heart transplantation: incidence, risk factors and impact on clinical outcome. Circ J. 2017;81(6):806–14.PubMed

22.

Nieuwenhuis MG, Kirkels JH. Predictability and other aspects of post-transplant diabetes mellitus in heart transplant recipients. J Heart Lung Transplant. 2001;20(7):703–8.PubMed

23.

Linder KE, Baker WL, Rochon C, May ST, Sheiner PA, Martin ST. Evaluation of posttransplantation diabetes mellitus after liver transplantation: assessment of insulin administration as a risk factor. Ann Pharmacother. 2016;50(5):369–75.PubMed

24.

Moon JI, Barbeito R, Faradji RN, Gaynor JJ, Tzakis AG. Negative impact of new-onset diabetes mellitus on patient and graft survival after liver transplantation: long-term follow up. Transplantation. 2006;82(12):1625–8.PubMed

25.

Hjelmesaeth J, Hartmann A, Kofstad J, Stenstrom J, Leivestad T, Egeland T, et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation. 1997;64(7):979–83.PubMed

26.

von During ME, Jenssen T, Bollerslev J, Asberg A, Godang K, Eide IA, et al. Visceral fat is better related to impaired glucose metabolism than body mass index after kidney transplantation. Transpl Int. 2015;28(10):1162–71.

27.

Walczak DA, Calvert D, Jarzembowski TM, Testa G, Sankary HN, Thielke J, et al. Increased risk of post-transplant diabetes mellitus despite early steroid discontinuation in Hispanic kidney transplant recipients. Clin Transplant. 2005;19(4):527–31.PubMed

28.

Peracha J, Nath J, Ready A, Tahir S, Parekh K, Hodson J, et al. Risk of post-transplantation diabetes mellitus is greater in South Asian versus Caucasian kidney allograft recipients. Transpl Int. 2016;29(6):727–39.PubMed

29.

Chen Y, Sampaio MS, Yang JW, Min D, Hutchinson IV. Genetic polymorphisms of the transcription factor NFATc4 and development of new-onset diabetes after transplantation in Hispanic kidney transplant recipients. Transplantation. 2012;93(3):325–30.PubMed

30.

Ghisdal L, Baron C, Le Meur Y, Lionet A, Halimi J-M, Rerolle J-P, et al. TCF7L2 polymorphism associates with new-onset diabetes after transplantation. J Am Soc Nephrol. 2009;20(11):2459–67.PubMedPubMedCentral

31.

Tavira B, Coto E, Torres A, Diaz-Corte C, Diaz-Molina B, Ortega F, et al. Association between a common KCNJ11 polymorphism (rs5219) and new-onset posttransplant diabetes in patients treated with Tacrolimus. Mol Genet Metab. 2012;105(3):525–7.PubMed

32.

Kim YG, Ihm C-G, Lee TW, Lee SH, Jeong KH, Moon JY, et al. Association of genetic polymorphisms of interleukins with new-onset diabetes after transplantation in renal transplantation. Transplantation. 2012;93(9):900–7.PubMed

33.

Shivaswamy V, Boerner B, Larsen J. Post-transplant diabetes mellitus: causes, treatment, and impact on outcomes. Endocr Rev. 2016;37(1):37–61.PubMed

34.

Naing C, Mak JW, Ahmed SI, Maung M. Relationship between hepatitis C virus infection and type 2 diabetes mellitus: meta-analysis. World J Gastroenterol. 2012;18(14):1642–51.PubMedPubMedCentral

35.

Fabrizi F, Martin P, Dixit V, Bunnapradist S, Kanwal F, Dulai G. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: Meta-analysis of clinical studies. Am J Transplant. 2005.

36.

Baid-Agrawal S, Frei U, Reinke P, Schindler R, Kopp MA, Martus P, et al. Impaired insulin sensitivity as an underlying mechanism linking hepatitis C and posttransplant diabetes mellitus in kidney recipients. Am J Transplant. 2009;9(12):2777–84.PubMed

37.

Gourishankar S, Jhangri GS, Tonelli M, Wales LH, Cockfield SM. Development of diabetes mellitus following kidney transplantation: a Canadian experience. Am J Transplant. 2004;4(11):1876–82.PubMed

38.

Pirsch JD, Henning AK, First MR, Fitzsimmons W, Gaber AO, Reisfield R, et al. New-onset diabetes after transplantation: results from a double-blind early corticosteroid withdrawal trial. Am J Transplant. 2015;15(7):1982–90.PubMed

39.

Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ. 2005;331(7520):810.PubMedPubMedCentral

40.

Fuji S, Kim S-W, Mori S, Furuta K, Tanosaki R, Heike Y, et al. Decreased insulin secretion in patients receiving tacrolimus as GVHD prophylaxis after allogeneic hematopoietic SCT. Vol. 45, Bone marrow transplantation. England; 2010. pp. 405–6.

41.

Shivaswamy V, Bennett RG, Clure CC, Ottemann B, Davis JS, Larsen JL, et al. Tacrolimus and sirolimus have distinct effects on insulin signaling in male and female rats. Transl Res. 2014;163(3):221–31.PubMed

42.

Drachenberg CB, Klassen DK, Weir MR, Wiland A, Fink JC, Bartlett ST, et al. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation. 1999;68(3):396–402.PubMed

43.

Jhala US, Canettieri G, Screaton RA, Kulkarni RN, Krajewski S, Reed J, et al. cAMP promotes pancreatic β-cell survival via CREB-mediated induction of IRS2. Genes Dev. 2003;17:1575–80.PubMedPubMedCentral

44.

Soleimanpour SA, Crutchlow MF, Ferrari AM, Raum JC, Groff DN, Rankin MM, et al. Calcineurin signaling regulates human islet β-cell survival. J Biol Chem. 2010;285(51):40050–9.PubMedPubMedCentral

45.

Asberg A, Midtvedt K, Voytovich MH, Line P-D, Narverud J, Reisaeter AV, et al. Calcineurin inhibitor effects on glucose metabolism and endothelial function following renal transplantation. Clin Transplant. 2009;23(4):511–8.PubMed

46.

Rickels MR, Naji A, Teff KL. Insulin sensitivity, glucose effectiveness, and free fatty acid dynamics after human islet transplantation for type 1 diabetes. J Clin Endocrinol Metab. 2006;91(6):2138–44.PubMed

47.

Lima Mde L, Cruz T, Rodrigues LE, Bomfim O, Melo J, Correia R, et al. Serum and intracellular magnesium deficiency in patients with metabolic syndrome-Evidences for its relation to insulin resistance. Diabetes Res Clin Pract. 2009;83:257–62.PubMed

48.

Van Laecke S, Van Biesen W, Verbeke F, De Bacquer D, Peeters P, Vanholder R. Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. Am J Transplant. 2009;9:2140–9.PubMed

49.

Gyurus E, Kaposztas Z, Kahan BD. Sirolimus therapy predisposes to new-onset diabetes mellitus after renal transplantation: a long-term analysis of various treatment regimens. Transplant Proc. 2011;43(5):1583–92.PubMed

50.

Veroux M, Tallarita T, Corona D, Sinagra N, Giaquinta A, Zerbo D, et al. Conversion to sirolimus therapy in kidney transplant recipients with new onset diabetes mellitus after transplantation. Clin Dev Immunol. 2013;2013:496974.PubMedPubMedCentral

51.

Bell E, Cao X, Moibi JA, Greene SR, Young R, Trucco M, et al. Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. Diabetes. 2003;52(11):2731–9.PubMed

52.

Bussiere CT, Lakey JRT, Shapiro AMJ, Korbutt GS. The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells. Diabetologia. 2006;49(10):2341–9.PubMed

53.

Shivaswamy V, Bennett RG, Clure CC, Larsen JL, Hamel FG. Metformin improves immunosuppressant induced hyperglycemia and exocrine apoptosis in rats. Transplantation. 2013;95(2):280–4.PubMed

54.

Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM, et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science. 2012;335(6076):1638–43.PubMedPubMedCentral

55.

Krebs M, Brunmair B, Brehm A, Artwohl M, Szendroedi J, Nowotny P, et al. The Mammalian target of rapamycin pathway regulates nutrient-sensitive glucose uptake in man. Diabetes. 2007;56(6):1600–7.PubMed

56.

Einollahi B, Motalebi M, Salesi M, Ebrahimi M, Taghipour M. The impact of cytomegalovirus infection on new-onset diabetes mellitus after kidney transplantation: a review on current findings. J Nephropathol. 2014;3(4):139–48.PubMedPubMedCentral

57.

Schweer T, Gwinner W, Scheffner I, Schwarz A, Haller H, Blume C. High impact of rejection therapy on the incidence of post-transplant diabetes mellitus after kidney transplantation. Clin Transplant. 2014;28(4):512–9.PubMed

58.

Revanur VK, Jardine AG, Kingsmore DB, Jaques BC, Hamilton DH, Jindal RM. Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation. Clin Transplant. 2001;15(2):89–94.PubMed

59.

Cosio FG, Pesavento TE, Kim S, Osei K, Henry M, Ferguson RM. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int. 2002;62(4):1440–6.PubMed

60.

Wauters RP, Cosio FG, Suarez Fernandez ML, Kudva Y, Shah P, Torres VE. Cardiovascular consequences of new-onset hyperglycemia after kidney transplantation. Transplantation. 2012;94(4):377–82.PubMedPubMedCentral

61.

Cole EH, Johnston O, Rose CL, Gill JS. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol. 2008;3(3):814–21.PubMedPubMedCentral

62.

Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3(2):178–85.PubMed

63.

Gaynor JJ, Ciancio G, Guerra G, Sageshima J, Hanson L, Roth D, et al. Single-centre study of 628 adult, primary kidney transplant recipients showing no unfavourable effect of new-onset diabetes after transplant. Diabetologia. 2015;58(2):334–45.PubMed

64.

Dienemann T, Fujii N, Li Y, Govani S, Kosaraju N, Bloom RD, et al. Long-term patient survival and kidney allograft survival in post-transplant diabetes mellitus: a single-center retrospective study. Transpl Int. 2016;29(9):1017–28.PubMed

65.

Koselj M, Rott T, Koselj MK, Hvala A, Arnol M, Kandus A. De novo diabetic nephropathy on renal allografts. Transplant Proc. 2003;35(8):2919–21.PubMed

66.

Miles AM, Sumrani N, Horowitz R, Homel P, Maursky V, Markell MS, et al. Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes? Transplantation. 1998;65(3):380–4.PubMed

67.

Londero TM, Giaretta LS, Farenzena LP, Manfro RC, Canani LH, Lavinsky D, et al. Microvascular complications of posttransplant diabetes mellitus in kidney transplant recipients: a longitudinal study. J Clin Endocrinol Metab. 2019;104(2):557–67.PubMed

68.

Nolte Fong JV, Moore LW. Nutrition trends in kidney transplant recipients: the importance of dietary monitoring and need for evidence-based recommendations. Front Med. 2018;5:302.

69.

van Wijngaarden RPT, Overbeek JA, Heintjes EM, Schubert A, Diels J, Straatman H, et al. Relation between different measures of glycemic exposure and microvascular and macrovascular complications in patients with type 2 diabetes mellitus: an observational cohort study. Diabetes Ther [Internet]. 2017;8(5):1097–109. https://doi.org/10.1007/s13300-017-0301-4.

70.

Group DPPR, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet (London, England) [Internet]. 2009/10/29. 2009;374(9702):1677–86. https://www.ncbi.nlm.nih.gov/pubmed/19878986.

71.

Sharif A, Moore R, Baboolal K. Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia. Transplantation. 2008;85(3):353–8.PubMed

72.

Weight Aksoy N, Transplant Gain After Kidney. Exp Clin Transplant. 2016;14(Suppl 3):138–40.

73.

Van Laecke S, Nagler EV, Taes Y, Van Biesen W, Peeters P, Vanholder R. The effect of magnesium supplements on early post-transplantation glucose metabolism: a randomized controlled trial. Transpl Int. 2014;27(9):895–902.PubMed

74.

Van Laecke S, Caluwe R, Huybrechts I, Nagler EV, Vanholder R, Peeters P, et al. Effect of magnesium supplements on insulin secretion after kidney transplantation: a randomized controlled trial. Ann Transplant. 2017;22:524–31.PubMed

75.

Gursoy M, Koksal R, Karavelioglu D, Colak T, Gur G, Ozdemir N, et al. Pretransplantation alpha-interferon therapy and the effect of hepatitis C virus infection on kidney allograft recipients. Transplant Proc. 2000;32(3):580–2.PubMed

76.

Humar A, Lebranchu Y, Vincenti F, Blumberg EA, Punch JD, Limaye AP, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant. 2010;10(5):1228–37.PubMed

77.

Bhat M, Pasini E, Copeland J, Angeli M, Husain S, Kumar D, et al. Impact of immunosuppression on the metagenomic composition of the intestinal microbiome: a systems biology approach to post-transplant diabetes. Sci Rep. 2017;7(1):10277.PubMedPubMedCentral

78.

Weiss R, Fernandez E, Liu Y, Strong R, Salmon AB. Metformin reduces glucose intolerance caused by rapamycin treatment in genetically heterogeneous female mice. Aging (Albany NY). 2018;10(3):386–401.PubMedPubMedCentral

79.

Festuccia WT, Blanchard P-G, Belchior T, Chimin P, Paschoal VA, Magdalon J, et al. PPARgamma activation attenuates glucose intolerance induced by mTOR inhibition with rapamycin in rats. Am J Physiol Endocrinol Metab. 2014;306(9):E1046–54.PubMed

80.

Hecking M, Haidinger M, Doller D, Werzowa J, Tura A, Zhang J, et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol. 2012;23(4):739–49.PubMedPubMedCentral

81.

Werzowa J, Hecking M, Haidinger M, Lechner F, Doller D, Pacini G, et al. Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial. Transplantation. 2013;95(3):456–62.PubMed

82.

Snowsill TM, Moore J, Mujica Mota RE, Peters JL, Jones-Hughes TL, Huxley NJ, et al. Immunosuppressive agents in adult kidney transplantation in the National Health Service: a model-based economic evaluation. Nephrol Dial Transplant. 2017;32(7):1251–9.PubMedPubMedCentral

83.

Batista F, Auyanet I, Torregrosa J-V, Oppenheimer F. Long-term follow-up after conversion from tacrolimus to cyclosporin in renal transplant patients with new-onset diabetes mellitus after transplantation. Transplant Proc. 2012;44(9):2582–4.PubMed

84.

Karpe KM, Talaulikar GS, Walters GD. Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients. Cochrane database Syst Rev. 2017;7:CD006750.

85.

Sharif A, Shabir S, Chand S, Cockwell P, Ball S, Borrows R. Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation. J Am Soc Nephrol. 2011;22(11):2107–18.PubMedPubMedCentral

86.

Sommerer C, Witzke O, Lehner F, Arns W, Reinke P, Eisenberger U, et al. Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials. BMC Nephrol. 2018;19(1):237.PubMedPubMedCentral

87.

Masson P, Henderson L, Chapman JR, Craig JC, Webster AC. Belatacept for kidney transplant recipients. Cochrane database Syst Rev. 2014;(11):CD010699.

88.

Sharif A. Should metformin be our antiglycemic agent of choice post-transplantation? Am J Transplant. 2011;11(7):1376–81.PubMed

89.

Potluri K, Hou S. Obesity in kidney transplant recipients and candidates. Am J Kidney Dis. 2010;56(1):143–56.PubMed

90.

Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005;(3):CD002966.

91.

Peters N, Jay N, Barraud D, Cravoisy A, Nace L, Bollaert P-E, et al. Metformin-associated lactic acidosis in an intensive care unit. Crit Care. 2008;12(6):R149.PubMedPubMedCentral

92.

Stephen J, Anderson-Haag TL, Gustafson S, Snyder JJ, Kasiske BL, Israni AK. Metformin use in kidney transplant recipients in the United States: an observational study. Am J Nephrol. 2014;40(6):546–53.PubMed

93.

Kurian B, Joshi R, Helmuth A. Effectiveness and long-term safety of thiazolidinediones and metformin in renal transplant recipients. Endocr Pract. 2008;14(8):979–84.PubMed

94.

Vanhove T, Remijsen Q, Kuypers D, Gillard P. Drug-drug interactions between immunosuppressants and antidiabetic drugs in the treatment of post-transplant diabetes mellitus. Transplant Rev (Orlando). 2017;31(2):69–77.PubMed

95.

Azoulay L, Suissa S. Sulfonylureas and the risks of cardiovascular events and death: a methodological meta-regression analysis of the observational studies. Diabetes Care. 2017;40(5):706–14.PubMed

96.

Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab. 2005;90(1):501–6.PubMed

97.

Tuerk TR, Bandur S, Nuernberger J, Kribben A, Mann K, Philipp T, et al. Gliquidone therapy of new-onset diabetes mellitus after kidney transplantation. Clin Nephrol. 2008;70(1):26–32.PubMed

98.

Turk T, Pietruck F, Dolff S, Kribben A, Janssen OE, Mann K, et al. Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. Am J Transplant. 2006;6(4):842–6.PubMed

99.

Villanueva G, Baldwin D. Rosiglitazone therapy of posttransplant diabetes mellitus. Transplantation. 2005;80(10):1402–5.PubMed

100.

Luther P, Baldwin DJ. Pioglitazone in the management of diabetes mellitus after transplantation. Am J Transplant. 2004;4(12):2135–8.PubMed

101.

Naylor KL, Jamal SA, Zou G, McArthur E, Lam NN, Leslie WD, et al. Fracture incidence in adult kidney transplant recipients. Transplantation. 2016;100(1):167–75.PubMed

102.

Haidinger M, Antlanger M, Kopecky C, Kovarik JJ, Saemann MD, Werzowa J. Post-transplantation diabetes mellitus: evaluation of treatment strategies. Clin Transplant. 2015;29(5):415–24.PubMed

103.

Boerner BP, Miles CD, Shivaswamy V. Efficacy and safety of sitagliptin for the treatment of new-onset diabetes after renal transplantation. Int J Endocrinol. 2014;2014:617638.PubMedPubMedCentral

104.

Strom Halden TA, Asberg A, Vik K, Hartmann A, Jenssen T. Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation. Nephrol Dial Transplant. 2014;29(4):926–33.PubMed

105.

Haidinger M, Werzowa J, Hecking M, Antlanger M, Stemer G, Pleiner J, et al. Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation—a randomized, double-blind, placebo-controlled trial. Am J Transplant. 2014;14(1):115–23.PubMed

106.

Gueler I, Mueller S, Helmschrott M, Oeing CU, Erbel C, Frankenstein L, et al. Effects of vildagliptin (Galvus(R)) therapy in patients with type 2 diabetes mellitus after heart transplantation. Drug Des Devel Ther. 2013;7:297–303.PubMedPubMedCentral

107.

Sanyal D, Gupta S, Das P. A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting. Indian J Endocrinol Metab. 2013;17(Suppl 1):S203–5.PubMedPubMedCentral

108.

Halden TAS, Egeland EJ, Asberg A, Hartmann A, Midtvedt K, Khiabani HZ, et al. GLP-1 restores altered insulin and glucagon secretion in posttransplantation diabetes. Diabetes Care. 2016;39(4):617–24.PubMed

109.

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.PubMedPubMedCentral

110.

Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.PubMed

111.

Hernandez AF, Green JB, Janmohamed S, D’Agostino RBS, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet (London, England). 2018;392(10157):1519–29.

112.

Pinelli NR, Patel A, Salinitri FD. Coadministration of liraglutide with tacrolimus in kidney transplant recipients: a case series. Vol. 36, Diabetes care. United States; 2013. p. e171-2.

113.

Singh P, Taufeeq M, Pesavento TE, Washburn K, Walsh D, Meng S. Comparison of two glucagon-like-peptide-1 analogs (GLP-1) dulaglutide vs liraglutide for the management of diabetes in solid organ transplant (SOT). Diabetes Obes Metab. 2020 (Epub ahead of print).

114.

Yates CJ, Fourlanos S, Colman PG, Cohney SJ. Screening for new-onset diabetes after kidney transplantation: limitations of fasting glucose and advantages of afternoon glucose and glycated hemoglobin. Transplantation. 2013;96(8):726–31.PubMed

115.

Cehic MG, Muir CA, Greenfield JR, Hayward C, Jabbour A, Keogh A, et al. Efficacy and safety of empagliflozin in the management of diabetes mellitus in heart transplant recipients. Transplant direct. 2019;5(5):e450.PubMedPubMedCentral

116.

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.PubMed

117.

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57.PubMed

118.

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57.PubMed

119.

Devineni D, Vaccaro N, Murphy J, Curtin C, Mamidi RNVS, Weiner S, et al. Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Int J Clin Pharmacol Ther. 2015;53(2):115–28.PubMed

120.

Jin J, Jin L, Luo K, Lim SW, Chung BH, Yang CW. Effect of empagliflozin on tacrolimus-induced pancreas islet dysfunction and renal injury. Am J Transplant. 2017;17(10):2601–16.PubMed

121.

Rubino F, Nathan DM, Eckel RH, Schauer PR, Alberti KGMM, Zimmet PZ, et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care. 2016;39(6):861–77.

122.

Chen JH, Lee CH, Chang CM, Yin WY. Successful management of new-onset diabetes mellitus and obesity with the use of laparoscopic sleeve gastrectomy after kidney transplantation-a case report. Transplant Proc. 2016;48(3):938–9.PubMed

123.

Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B, et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J. 2004;25(2):166–81.

124.

Smith SCJ, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113(19):2363–72.PubMed

125.

Hricik DE, Mayes JT, Schulak JA. Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia. Am J Kidney Dis. 1991;18(3):353–8.PubMed

126.

Marcen R, Chahin J, Alarcon A, Bravo J. Conversion from cyclosporine microemulsion to tacrolimus in stable kidney transplant patients with hypercholesterolemia is related to an improvement in cardiovascular risk profile: a prospective study. Transplant Proc. 2006;38(8):2427–30.PubMed

127.

Ma KL, Ruan XZ, Powis SH, Chen Y, Moorhead JF, Varghese Z. Sirolimus modifies cholesterol homeostasis in hepatic cells: a potential molecular mechanism for sirolimus-associated dyslipidemia. Transplantation. 2007;84(8):1029–36.PubMed

128.

KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(Suppl 3):S1–155.

129.

Kasiske B, Cosio FG, Beto J, Bolton K, Chavers BM, Grimm RJ, et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant. 2004;4(Suppl 7):13–53.PubMed

130.

Holdaas H, Fellstrom B, Cole E, Nyberg G, Olsson AG, Pedersen TR, et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant. 2005;5(12):2929–36.PubMed

131.

Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995;333(10):621–7.PubMed

132.

Wenke K, Meiser B, Thiery J, Nagel D, von Scheidt W, Steinbeck G, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation. 1997;96(5):1398–402.PubMed

133.

Navaneethan SD, Perkovic V, Johnson DW, Nigwekar SU, Craig JC, Strippoli GFM. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane database Syst Rev. 2009;(2):CD005019.

134.

Subramaniam S, Zell JA, Kunz PL. Everolimus causing severe hypertriglyceridemia and acute pancreatitis. J Natl Compr Canc Netw. 2013;11(1):5–9.PubMed

135.

Lim AKH, Manley KJ, Roberts MA, Fraenkel MB. Fish oil for kidney transplant recipients. Cochrane database Syst Rev. 2007;(2):CD005282.

136.

Page RL 2nd, Miller GG, Lindenfeld J. Drug therapy in the heart transplant recipient: part IV: drug–drug interactions. Circulation. 2005;111(2):230–9.PubMed

137.

Shaw SM, Chaggar P, Ritchie J, Shah MKH, Baynes AC, O’Neill N, et al. The efficacy and tolerability of ezetimibe in cardiac transplant recipients taking cyclosporin. Transplantation. 2009;87(5):771–5.PubMed

138.

Gonwa T, Mendez R, Yang HC, Weinstein S, Jensik S, Steinberg S. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. Transplantation. 2003;75(8):1213–20.PubMed

139.

Gruessner RW, Sutherland DE, Parr E, Humar A, Gruessner AC. A prospective, randomized, open-label study of steroid withdrawal in pancreas transplantation—a preliminary report with 6-month follow-up. Transplant Proc. 2001;33(1–2):1663–4.PubMed

140.

Eisenga MF, Zelle DM, Sloan JH, Gaillard CAJM, Bakker SJL, Dullaart RPF. High serum PCSK9 is associated with increased risk of new-onset diabetes after transplantation in renal transplant recipients. Diabetes Care. 2017;40(7):894–901.PubMed

141.

K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(5 Suppl 1):S1–290.

142.

Opelz G, Dohler B. Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant. 2005;5(11):2725–31.PubMed

143.

Opelz G, Zeier M, Laux G, Morath C, Dohler B. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol. 2006;17(11):3257–62.

144.

Cross NB, Webster AC, Masson P, O’Connell PJ, Craig JC. Antihypertensive treatment for kidney transplant recipients. Cochrane database Syst Rev. 2009;(3):CD003598.

Title: Post-Transplantation Diabetes Mellitus
Authors: Syed Haris Ahmed
Kathryn Biddle
Titus Augustine
Shazli Azmi
Publication date: 01-04-2020
Publisher: Springer Healthcare
Keywords: Insulins
Diabetes
Insulins
Calcineurin Inhibitors
mTOR-Inhibitors
Tacrolimus
Published in: Diabetes Therapy / Issue 4/2020
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI: https://doi.org/10.1007/s13300-020-00790-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2020

EQ-5D-3L Decrements by Diabetes Complications and Comorbidities in China

Expert Opinion on the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective

Diabetic Neuropathy Collection: Treatment of Diabetic Neuropathy

Comparison of the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy and Rosuvastatin Monotherapy on Lipoprotein in Patients With Type 2 Diabetes: Multicenter Randomized Controlled Study

Diabetic Neuropathy Collection: Progress in Diagnosis and Screening

Improved Framingham Risk Scores of Patients with Type 2 Diabetes Mellitus in the Beijing Community: A 10-Year Prospective Study of the Effects of Multifactorial Interventions on Cardiovascular Risk Factors (The Beijing Communities Diabetes Study 22)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials